MEP21108A - Derivati furosemida kao modulatori hm74n i njihova primjena liječenju inflamacije - Google Patents

Derivati furosemida kao modulatori hm74n i njihova primjena liječenju inflamacije

Info

Publication number
MEP21108A
MEP21108A MEP-211/08A MEP21108A MEP21108A ME P21108 A MEP21108 A ME P21108A ME P21108 A MEP21108 A ME P21108A ME P21108 A MEP21108 A ME P21108A
Authority
ME
Montenegro
Prior art keywords
modulators
inflammation
treatment
furosemide
derivatives
Prior art date
Application number
MEP-211/08A
Other languages
English (en)
Inventor
Anne Minnich
Theresa Kuntzweiler
Haifeng Eishingdrelo
Michael Angelastro
Han-Jochen Lang
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MEP21108A publication Critical patent/MEP21108A/bs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Ćelije domaćini koji eksprimuju HM74 su korišćene za dobijanje furosemid-sličnih molekula koja imaju agonističku aktivnost i sljedeću strukturnu formulu:
MEP-211/08A 2004-02-20 2005-02-10 Derivati furosemida kao modulatori hm74n i njihova primjena liječenju inflamacije MEP21108A (bs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54601104P 2004-02-20 2004-02-20
PCT/US2005/004108 WO2005082350A1 (en) 2004-02-20 2005-02-10 Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation

Publications (1)

Publication Number Publication Date
MEP21108A true MEP21108A (bs) 2010-06-10

Family

ID=34910746

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-211/08A MEP21108A (bs) 2004-02-20 2005-02-10 Derivati furosemida kao modulatori hm74n i njihova primjena liječenju inflamacije

Country Status (24)

Country Link
US (2) US7232811B2 (bs)
EP (1) EP1718292A1 (bs)
JP (1) JP2007523166A (bs)
KR (1) KR20060127141A (bs)
CN (1) CN1921845A (bs)
AR (1) AR047747A1 (bs)
AU (1) AU2005216879B2 (bs)
BR (1) BRPI0506792A (bs)
CA (1) CA2557444A1 (bs)
CR (1) CR8528A (bs)
EC (1) ECSP066777A (bs)
IL (1) IL177086A (bs)
MA (1) MA28373A1 (bs)
ME (1) MEP21108A (bs)
MX (1) MXPA06008612A (bs)
NO (1) NO20064237L (bs)
NZ (1) NZ548830A (bs)
RS (1) RS20060473A (bs)
RU (1) RU2006133540A (bs)
SG (1) SG164305A1 (bs)
TN (1) TNSN06234A1 (bs)
TW (1) TW200538109A (bs)
WO (1) WO2005082350A1 (bs)
ZA (1) ZA200606679B (bs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
EP1968603A4 (en) * 2006-01-03 2013-01-16 Algebra Inc THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS
US7897601B2 (en) * 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
CA2669117A1 (en) 2006-10-26 2008-05-02 Gary A. Flynn Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CA2692268A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
LT6401B (lt) * 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875150A (en) 1969-04-29 1975-04-01 Leo Pharm Prod Ltd New sulfamyl-anthranilic acids
GB1260155A (en) * 1969-04-29 1972-01-12 Leo Pharm Prod Ltd Sulphonamido anthranilic acid derivatives
AT324318B (de) * 1971-02-15 1975-08-25 Dumex Ltd As Verfahren zur herstellung von furanderivaten
DE2247828A1 (de) * 1972-09-29 1974-04-04 Hoechst Ag Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung
DE2406972C3 (de) * 1974-02-14 1979-07-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2718871C3 (de) * 1977-04-28 1980-07-17 Hoechst Ag, 6000 Frankfurt N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
DE3006686A1 (de) * 1980-02-22 1981-08-27 Hoechst Ag, 6000 Frankfurt 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
WO1998056820A1 (en) * 1997-06-12 1998-12-17 Smithkline Beecham Corporation Hm74a receptor
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
DE10060809A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20030109673A1 (en) * 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
ECSP066777A (es) 2006-11-16
US20070213391A1 (en) 2007-09-13
IL177086A (en) 2010-06-16
AU2005216879B2 (en) 2009-12-10
BRPI0506792A (pt) 2007-05-22
IL177086A0 (en) 2006-12-10
KR20060127141A (ko) 2006-12-11
US20050187280A1 (en) 2005-08-25
WO2005082350A1 (en) 2005-09-09
TNSN06234A1 (en) 2007-12-03
MA28373A1 (fr) 2006-12-01
AU2005216879A1 (en) 2005-09-09
EP1718292A1 (en) 2006-11-08
AR047747A1 (es) 2006-02-15
US7556931B2 (en) 2009-07-07
JP2007523166A (ja) 2007-08-16
CA2557444A1 (en) 2005-09-09
NZ548830A (en) 2010-03-26
MXPA06008612A (es) 2007-01-25
NO20064237L (no) 2006-09-19
RS20060473A (en) 2008-08-07
TW200538109A (en) 2005-12-01
CR8528A (es) 2007-06-08
CN1921845A (zh) 2007-02-28
WO2005082350A8 (en) 2005-12-08
ZA200606679B (en) 2008-01-30
RU2006133540A (ru) 2008-03-27
SG164305A1 (en) 2010-09-29
US7232811B2 (en) 2007-06-19

Similar Documents

Publication Publication Date Title
MEP21108A (bs) Derivati furosemida kao modulatori hm74n i njihova primjena liječenju inflamacije
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
MX2009011364A (es) Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2-il) y n-(5-heteroarilcroman-3-il)carboxamida para el tratamiento del dolor.
MX2012015096A (es) Compuestos heterociclicos fusionados como moduladores del canal ion.
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
BRPI0508464B8 (pt) sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201101424A1 (ru) Антимикробные композиции и способы их применения
EA201370191A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
EA200970841A1 (ru) Фармацевтическое применение замещенных амидов
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
NI200700056A (es) Nuevos derivados de sulfamidas de heteroaril benzo-fundido útiles como agentes anticonvulsivos
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA201170979A1 (ru) Карбоксамидные соединения и способы их применения
CL2012003624A1 (es) Uso estético de acido cicórico y sus derivados para regular la pigmentacion de la piel; kit para tratar y/o prevenir trastornos de pigmentacion de la piel y/o imperfecciones de la piel.
CY1111588T1 (el) Υποκατεστημενα καρβοξαμιδια ως ανταγωνιστες μεταβολοτροπου υποδοχεα ομαδας ι
ATE531703T1 (de) Benzochromenderivate
BRPI0508471A8 (pt) compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos
EA201200086A1 (ru) Замещенные 2-карбоксамиды циклоаминомочевин
NO20064214L (no) Oxydecahydronaphthalen-modulatorer for HM74